INDIANAPOLIS—Donald A. Zakrowski, Senior Vice President of Finance and Chief Accounting Officer at Eli Lilly & Co. (NYSE:LLY), has reported the sale of 1,000 shares of the company’s common stock. The transaction, executed on March 13, 2025, was completed at a price of $818.24 per share, amounting to a total sale value of $818,240.
Following this transaction, Zakrowski retains direct ownership of 5,839.659 shares of Eli Lilly stock. Additionally, he holds 1,720.21 shares indirectly through a 401(k) plan. The sale was conducted under a Rule 10b5-1 trading plan, which Zakrowski had adopted on November 20, 2024.
In other recent news, Eli Lilly has been the focus of several significant developments. Morgan Stanley reaffirmed its Overweight rating for Eli Lilly, maintaining a price target of $1,146.00, indicating confidence in the company’s competitive position within the diabetes care market. Meanwhile, a U.S. federal judge denied an injunction that would have allowed compounding pharmacies to produce copies of Eli Lilly’s weight-loss drug, Zepbound, upholding the FDA’s prohibition. This legal decision supports Eli Lilly’s market exclusivity for Zepbound in the U.S.
Bernstein analysts also reiterated their Outperform rating for Eli Lilly, with a price target of $1,100.00, citing expectations for impactful data readouts in 2025 and confidence in the company’s development pipeline, including promising candidates like Orforglipron and Retatrutide. Additionally, Eli Lilly announced a substantial $27 billion investment in U.S. manufacturing, furthering its commitment to domestic production expansion. This investment aligns with strategic goals to enhance American manufacturing and national health.
These recent developments highlight Eli Lilly’s proactive market strategies and its potential for sustained growth. The company’s actions are viewed as reinforcing its leadership in the GLP1 market and bolstering its prospects for commercial success.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.